Our program is highly competitive. Due to our individualized, hands-on approach to consulting we can accept only a limited number of companies into the GALS program.

Admission Criteria

Applicants must be promising emerging life science companies that have great potential to benefit from the GALS program. Companies must have an affiliation with Germany, i.e. incorporated in Germany or with significant operations there. Applicants must develop a product or service in (at least) one of the five supported life science segments: Digital Health, Medical Devices, Diagnostics, Therapeutics, or Platform Technologies. The stage of the company’s growth is relevant; the age of the company is not.

Application

The GALS application consists of around 20 questions about your company, team, technology, and business plan. It only takes a couple of hours to complete. We also request that companies submit additional materials with their application, such as a slide deck and a product demo (if available). Companies apply to the GALS program via the external platform SurveyMonkey.

Deadlines

GALS accepts companies into the program on a rolling basis. Companies can apply any time. Applications are reviewed by the Selection Committee every 6-8 weeks. Program start dates are flexible.

Next application deadline: November 11, 2018

Selection Process

The GALS Selection Committee meets approximately every 6-8 weeks to evaluate new applications. GALS then invites selected promising companies to an in-person workshop for a further assessment of their technology and business strategy.

APPLY NOW

Selection Committee

Matthias Notz
Matthias Notz

Read Bio
XMatthias Notz
Member of GALS Selection Committee

SHORT BIO
Matthias Notz is the Managing Director at the German Entrepreneurship GmbH in Munich. He works as a consultant and senior project manager at the interface between start-ups, universities and industries. He has been involved in various projects with renowned companies and educational institutions in the fields of intra- and entrepreneurship advancement, in the setup of strategic partnerships and in fundraising. Matthias has contributed substantially to the development of fundraising and also to the partnership structures at the LMU Entrepreneurship Center which supports young and innovative German startups by providing them with infrastructure, training and networks – and he passionately drives its continuous progress.

At the German Accelerator, Matthias is responsible for the acquisition and management of partners- and sponsorships based in Germany, as well as the budgeting and financial reporting activities in cooperation with the German Federal Ministry for Economic Affairs and Energy. He believes that strong ties with both German and U.S. network partners and also a sound financial basis, will promote the further success of the German Accelerator, and thus strengthen the transatlantic entrepreneurship ecosystem.

Matthias graduated with highest honors in Business Administration and has continuously broadened his knowledge and expertise far beyond the academic education through his previous work experiences in both public and private organizations. He has held numerous speeches, seminars and workshops for startups, universities and companies nationwide and enthusiastically represents his family’s tradition of entrepreneurial thinking and keeping a can-do mentality.
Dietmar Harhoff
Dietmar Harhoff

Read Bio
XDietmar Harhoff
Member of GALS Advisory Council
Member of GALS Selection Committee

SHORT BIO
Since 28 February 2007 Dietmar Harhoff has been chairman of the Commission of Experts for Research and Innovation that has been appointed by the Federal Government of Germany. Dietmar Harhoff is director at the Max Planck Institute for Innovation and Competition and head of the department Munich Center for Innovation and Entrepreneurship Research (MCIER). He is Honorary Professor at the Ludwig Maximilian University in Munich (LMU) and Academic Director of the Center for Entrepreneurship at the LMU. From 1998 to 2013 he was professor of business administration at the LMU and chaired the Institute for Innovation Research, Technology Management and Entrepreneurship (INNO-tec). After his training as a graduate engineer in mechanical engineering at the University of Dortmund, he first worked as a research engineer in the UK and Germany. After that he finished a master degree as McCloy scholar at Harvard University, followed by a doctoral degree at the Massachusetts Institute of Technology (MIT). From 1991 to 1998 he initially worked as research group manager and then – from 1995 – as vice director at the Center for European Economic Research in Mannheim. He habilitated in 1996 at the Department of Economics at the University of Mannheim. In 1998 he took his current position at the University of Munich. In October 2007, Prof. Harhoff was granted a senior research professorship for four years. From January 2010 to September 2010 he was Visiting Professor at Stanford University in the U.S.

As a scientific adviser he is working for a number of public and private organizations, among others he is a member of the Standing Advisory Committee (SACEPO) of the European Patent Office (EPO) and a member of the Scientific Advisory Board at the Federal Ministry of Economics and Technology (BMWi). In 2007, Prof. Harhoff was nominated by Managing Intellectual Property Magazine to be one of the 50 most influential people in the field of Intellectual Property. Since 2008, he is an elected member of acatech (Deutsche Akademie der Technikwissenschaften) and since 2010 he is also a member of the National Academy of Sciences Leopoldina (Deutsche Akademie der Naturforscher Leopoldina).
Ute Fink
Ute Fink

Read Bio
XUte Fink
Member of GALS Selection Committee

SHORT BIO
Ute Fink graduated in process engineering and technical chemistry at the University of Applied Sciences at Nuremberg. She received her Ph.D. in biochemistry at Eberhard-Karls University at Tübingen. Following her academic career she was a staff scientist and project leader at various biotech companies where she was responsible for R&D and market introduction of new products as well as business development. As a consultant to renowned diagnostics and pharma companies she applied her broad expertise in project management, technology scouting and transfer, which concluded in numerous successful partnering deals. She has also been active as reviewer and referee for venture capitalists and project management agencies. Since 2007 Ute Fink has worked for PtJ, a project management agency to various German federal and state ministries. Her team offers entrepreneurial support to academic projects and young companies that are funded as part of the life sciences start-up programme GO-Bio (Gründungsoffensive Biotechnologie) of the German Federal Ministry of Education and Research (BMBF).
Stefan Drews
Stefan Drews

Read Bio
XStefan Drews
Member of GALS Selection Committee

SHORT BIO
Stefan Drews works for the German Federal Ministry for Economic Affairs and Energy and is responsible for the execution of German Accelerator Program since 2013. Prior to that position he worked for the European Commission in Brussels and the Bertelsmann Foundation. He holds a Ph.D. in economics and currently lives and works in Berlin, Germany.
Philipp Angenendt
Philipp Angenendt

Read Bio
XPhilipp Angenendt
Member of GALS Selection Committee

SHORT BIO
Philipp is the Director of VWRCATALYST Germany. He possesses a deep knowledge in technology management from his time as Director of Pharmaceutical Sales and Technology & Prokurist at Sysmex Inostics GmbH. Through his previous role as Chief Technology Officer, Prokurist & Director of Global Operations at Sysmex Inostics GmbH, Philipp was responsible for global operations in China, Germany, and the United States of America. Philipp combines his demonstrated excellence in the areas of Molecular Diagnostics, Life Science, Biochemistry, and Pharma with a proven track record in sales and marketing. He also has strong experience in the setup and organization of business units.

Philipp holds a B.S. in Biotechnology from Mannheim University of Applied Sciences. He also earned his Ph.D. in Biochemistry from Max-Planck-Institute for Molecular Genetics and received the Dieter-Rampacher Price Award distinction as a nationwide youngest graduate with outstanding thesis. Following his Postdoctoral Fellow at the German Cancer Research Center in Heidelberg, Germany, Philipp received a Graduate Certificate in Management and Leadership in the Life Sciences from John Hopkins Carey Business School.  
Greg Dombal
Greg Dombal

Read Bio
XGreg Dombal Member of GALS Selection Committee SHORT BIO Greg joined Halloran Consulting Group in 2007. He focuses on helping emerging companies navigate challenges in product development while establishing appropriate clinical, regulatory, and compliance structures. Greg represents clients to worldwide regulatory agencies and routinely functions as an on-demand Head of Regulatory, Clinical, or Development. Greg pairs over 25 years’ experience in worldwide regulatory affairs, quality assurance and clinical development with a willingness to challenge conventional, conservative approaches and find the best solution for each company and their products. Before joining Halloran, Greg was responsible for the regulatory, quality assurance, and clinical groups at ArQule. At its peak, the programs he was responsible for encompassed 17 clinical studies with annual budgets in excess of $25 million. Over his career, Greg has successfully filed over 45 clinical trial applications (IND, IDE or equivalent), attended over 75 regulatory agency meetings, presented to multiple Advisory Committees and helped companies respond to Warning Letters, 522 Orders, and Clinical Hold notices. He has obtained Orphan Drug designation and/or Fast Track designation for fifteen individual products, successfully negotiated multiple Special Protocol Agreements, and has extensive involvement with NDA/MAA submissions resulting in multiple product approvals. Greg holds a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill. He is also a certified PROSCI change management professional from Colorado State University. He is involved with many non-profit organizations; as an advisor to the Fit Girls Foundation a 501(c)(3) building strong, brave and fit young women; as a past president of Marblehead Youth Baseball, and was a founding board member of the TriROK Foundation a 501(c)(3) dedicated to eliminating childhood obesity.
Michael Bogenstaetter
Michael Bogenstaetter

Read Bio
XMichael Bogenstaetter

Member of GALS Selection Committee

Short Bio

Michael Bogenstaetter has over 15 years experience in Biopharma R&D and commercialization of innovative therapies having worked in different leadership roles with companies such as Johnson & Johnson, Novartis and Sanofi and having advised leading Biopharma organizations as member of the Health Care practice of The Boston Consulting Group. Currently, Michael is an independent management consultant in the Life Sciences area.

Michael holds a Ph.D. in organic chemistry from University of Munich and a full time MBA from London Business School.

Thomas Kiessling
Thomas Kiessling

Read Bio
XThomas Kiessling

Member of GALS Advisory Council
Member of GALS Selection Committee

Short Bio

Thomas is a technology entrepreneur with 25 years of experience in product and business development in software, hardware, and online consumer products.

Thomas was the CTO / CIO of Securitas Direct, a Bain Capital & Hellman & Friedman company until the end of 2015. Securitas Direct is a private-equity owned supplier of home alarms and connected services for protected homes, sold to Hellman & Friedman in October 2015. Prior to this position Thomas was Chief Product and Innovation Officer for Deutsche Telekom / T Mobile group.

Thomas has also worked in CTO / product development roles for bwin Interactive Entertainment AG, Amadeus, and GlobalOne HQ, managing growth businesses and bringing transformational change.

Thomas holds an MA in Economics and was a Fulbright Scholar at the American University, Washington D.C. He also earned a Master in Telecommunications Network Engineering in Paris, France before receiving his Ph.D. in Telecommunications Economics from University of Stuttgart, Germany.

Christoph Lengauer
Christoph Lengauer

Read Bio
XChristoph Lengauer

CEO of German Accelerator Life Sciences

Short Bio

Christoph is executive vice president at Blueprint Medicines (BPMC) in Cambridge, MA. He has a proven record in cancer drug discovery, including contributing to 22 development candidates, 13 drugs or programs that reached first-in-human clinical trials and three approved drugs. He joined Blueprint Medicines from Sanofi, where he was vice president and global head of oncology drug discovery and preclinical development. Before joining Sanofi, Christoph was executive director and senior unit head of oncology discovery at the Novartis Institutes for Biomedical Research (NIBR). Prior to Novartis, Christoph was an associate professor at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine where he worked with Drs. Bert Vogelstein and Ken Kinzler for more than ten years.

Christoph discovered that all cancers are genetically unstable and was involved in the identification of several oncogenic driver genes. He has authored more than hundred scientific articles published in top-tier scientific journals, including Nature and Science. He is a strong and outspoken advocate of patients’ rights and is featured in the New York Times bestseller “The Immortal Life of Henrietta Lacks.” Christoph studied human genetics in Salzburg, Austria, and received his Ph.D. from the University of Heidelberg, Germany and his MBA with a focus on medical services management from the Johns Hopkins Carey Business School. Christoph has received numerous awards including the Boveri Award in Cancer Genetics, the Benjamin Baker Scholar award, and a V Foundation scholarship. He was awarded the Novartis Oncology’s President’s Award for top innovator and has been elected to membership in the Johns Hopkins Society of Scholars.

Christoph is also venture partner at Third Rock Ventures. In fall of 2015 he was appointed by the German Ministry for Economic Affairs & Energy to lead the build out of the German Accelerator Life Sciences in Cambridge.

Marcus Schabacker
Marcus Schabacker

Read Bio
X

Dr. Schabacker currently serves as Corporate Vice President and Chief Scientific Officer at Baxter Healthcare Corporation. In this role, he leads the Research & Development (R&D), Regulatory Affairs, Program Management Office, Global Patient Safety, Medical Affairs, Life Science and Clinical Development organizations for Baxter. He is responsible for driving innovation, enhancing scientific technical and medical capabilities to ensure a strong foundation of safety, clinical development, and regulatory support.

Prior to his appointment as CSO, Dr. Schabacker joined Baxter in March 2011 as the head of R&D for Baxter’s Medical Products business unit. He led the integration of multiple R&D teams into one global organization and placed R&D resources closer to its global customer base, including those in fast- growing emerging markets such as China and India.

Before joining Baxter, Dr. Schabacker held the position of Senior Vice President and Chief Scientific Officer at ConvaTec, Inc. – a leading developer and marketer of medical technologies in ostomy care, wound therapeutics, continence and critical care, and infusion devices. Dr. Schabacker’ s previous roles include Corporate Vice President R&D at B. Braun Medical and Senior Medical Officer at Mafikeng General Hospital, South Africa where he established and led the Anesthesia and Intensive Care Medicine Department and also served as the Medical Lead for Disaster Planning.

Dr. Schabacker has an MD and a Doctorate in anesthesia from Medical University of Lübeck in Germany and certifications in Anesthesiology, Disaster Medicine, and Emergency Medicine.

Derek Young
Derek Young

Read Bio
XDerek Young

Member of GALS Selection Committee

Short Bio

Derek is an entrepreneur and innovator in the healthcare sector. He is a named inventor of over 30 patents with commercial success globally. Derek has successfully co-founded a number of European medical device startup companies including Medtech, Advanced Surgical Concepts and Haptica before spinning into the Royal College of Surgeons (RCSI) in Dublin. While there Derek established a Healthcare Innovation Hub to develop ideas received from clinicians and inventors in Europe and Internationally.

Derek has spear-headed and completed at least 12 Medical Device Licenses deals with key International Healthcare MNC over the last 12 years, completing deals with companies such as Ethicon Endo Surgery, Johnson & Johnson, Covidien, Boston Scientific and CAE Healthcare.

Derek is Founder, CEO and key promoter of i360medical, which is a direct spin out of the Healthcare Innovation Hub that was converted to a for-profit commercial model with the support of the RCSI. I360medical is a European and US based Healthcare Solutions and Medical Device Innovation Company that provides its services to Global Hospital Systems, the Medical Device industry, and clinical communities.

He has gained significant partners and support, and has built an impressive global network of experienced professionals within the medical device and clinical sectors intending to deliver transformational innovation to commercialization change to the international Hospital Systems, Medical Device Industry and Clinical Community.

Derek has a background in Mechanical Engineering, Surgical Innovation and Business Development from the Austin Waldron and Dublin Institute of Technology in Ireland. He also holds a number of board positions on medical device companies and medical research groups at both a national and international level.